DNA methylation level of OPCML and SFRP1: a potential diagnostic biomarker of cholangiocarcinoma

被引:24
作者
Amornpisutt, Rattaya [1 ]
Proungvitaya, Siriporn [1 ,2 ]
Jearanaikoon, Patcharee [1 ,2 ]
Limpaiboon, Temduang [1 ,2 ]
机构
[1] Khon Kaen Univ, Ctr Res & Dev, Med Diagnost Labs, Fac Associated Med Sci, Khon Kaen 40002, Thailand
[2] Khon Kaen Univ, Liver Fluke & Cholangiocarcinoma Res Ctr, Fac Med, Khon Kaen 40002, Thailand
关键词
Biliary tract cancer; Liver cancer; Methylation-sensitive high-resolution melting; DNA methylation; Biomarkers; TUMOR-SUPPRESSOR; PROMOTER METHYLATION; CANCER; GENE; PATHWAY;
D O I
10.1007/s13277-015-3147-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cholangiocarcinoma (CCA) is a malignancy of the bile duct epithelium which is caused by liver fluke infection. The clinical symptoms of CCA were revealed as the disease progresses to advanced stage. Thus, specific diagnostic biomarkers are important for this fatal disease. We applied methylation-sensitive high-resolution melting (MS-HRM) to quantify DNA methylation levels of opioid binding protein/cell adhesion molecule-like gene (OPCML) and Secreted frizzled-related protein 1 (SFRP1) in 73 primary CCA and 10 adjacent normal tissues and evaluated the sensitivity, specificity, and accuracy of the assay. The median methylation level of OPCML in CCA was 38.7 % (ranged from 0 to 82.2 %) and of SFRP1 was 31.5 % (ranged from 0 to 86.2 %). Methylation cutoff values of OPCML and SFRP1 derived from adjacent normal tissue were 6.90 and 10.44 %, respectively. With these cutoff values, the area under curve (AUC) of OPCML was 0.932 (95 % CI 0.878-0.986) and of SFRP1 was 0.951 (95 % CI 0.905-0.996). The sensitivity, specificity, and accuracy of OPCML were 89.04, 100, and 90.36 %, respectively, and of SFRP1 were 83.56, 100, and 85.54 %, respectively. In conclusion, the DNA methylation levels of OPCML and SFRP1 could be potential biomarkers for diagnosis of CCA with high specificity, sensitivity, and accuracy, in particular for biopsy specimens. Further validation in noninvasive samples such as serum or plasma is warranted for clinical applicability, especially as early diagnostic biomarkers.
引用
收藏
页码:4973 / 4978
页数:6
相关论文
共 33 条
[1]   Validation of methylation-sensitive high resolution melting for the detection of DNA methylation in cholangiocarcinoma [J].
Amornpisutt, Rattaya ;
Sriraksa, Ruethairat ;
Limpaiboon, Temduang .
CLINICAL BIOCHEMISTRY, 2012, 45 (13-14) :1092-1094
[2]   Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? [J].
Baylin, SB ;
Ohm, JE .
NATURE REVIEWS CANCER, 2006, 6 (02) :107-116
[3]   Immunoglobulin-like cell adhesion molecules: Novel signaling players in epithelial ovarian cancer [J].
Bombardelli, Lorenzo ;
Cavallaro, Ugo .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2010, 42 (05) :590-594
[4]   Promoter methylation of SFRPs gene family in cervical cancer [J].
Chung, Ming-Tzeung ;
Sytwu, Huey-Kang ;
Yan, Ming-De ;
Shih, Yu-Lueng ;
Chang, Cheng-Chang ;
Yu, Mu-Hsien ;
Chu, Tang-Yuan ;
Lai, Hung-Cheng ;
Lin, Ya-Wen .
GYNECOLOGIC ONCOLOGY, 2009, 112 (02) :301-306
[5]   OPCML Is a Broad Tumor Suppressor for Multiple Carcinomas and Lymphomas with Frequently Epigenetic Inactivation [J].
Cui, Yan ;
Ying, Ying ;
van Hasselt, Andrew ;
Ng, Ka Man ;
Yu, Jun ;
Zhang, Qian ;
Jin, Jie ;
Liu, Dingxie ;
Rhim, Johng S. ;
Rha, Sun Young ;
Loyo, Myriam ;
Chan, Anthony T. C. ;
Srivastava, Gopesh ;
Tsao, George S. W. ;
Sellar, Grant C. ;
Sung, Joseph J. Y. ;
Sidransky, David ;
Tao, Qian .
PLOS ONE, 2008, 3 (08)
[6]   Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma [J].
Duarte-Pereira, Sara ;
Paiva, Filipa ;
Costa, Vera Lucia ;
Ramalho-Carvalho, Joao ;
Savva-Borclalo, Joana ;
Rodrigues, Angelo ;
Ribeiro, Franclim Ricardo ;
Silva, Vitor M. ;
Oliveira, Jorge ;
Henrique, Rui ;
Jeronimo, Carmen .
EUROPEAN JOURNAL OF CANCER, 2011, 47 (07) :1106-1114
[7]   Methylated genes as new cancer biomarkers [J].
Duffy, M. J. ;
Napieralski, R. ;
Martens, J. W. M. ;
Span, P. N. ;
Spyratos, F. ;
Sweep, F. C. G. J. ;
Brunner, N. ;
Foekens, J. A. ;
Schmitt, M. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (03) :335-346
[8]   The Advantages and Disadvantages of Sfrp1 and Sfrp2 Expression in Pathological Events [J].
Esteve, Pilar ;
Bovolenta, Paola .
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2010, 221 (01) :11-17
[9]  
Gatto M, 2010, WORLD J GASTROINTEST, V1, P12
[10]   Cholangiocarcinoma: Update and future perspectives [J].
Gatto, Manuela ;
Bragazzi, Maria Consiglia ;
Semeraro, Rossella ;
Napoli, Cristina ;
Gentile, Raffaele ;
Torrice, Alessia ;
Gaudio, Eugenio ;
Alvaro, Domenico .
DIGESTIVE AND LIVER DISEASE, 2010, 42 (04) :253-260